Stoke Therapeutics (STOK) Set to Announce Quarterly Earnings on Thursday

Stoke Therapeutics (NASDAQ:STOK) is anticipated to announce its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.9291) per share and revenue of $8.21 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. The firm had revenue of $9.32 million during the quarter, compared to the consensus estimate of $4.89 million. On average, analysts expect Stoke Therapeutics to post ($3.52) EPS for the current fiscal year and ($3.44) EPS for the next fiscal year.

Stoke Therapeutics Price Performance

STOK opened at $25.46 on Tuesday. The company has a market capitalization of $1.64 billion, a P/E ratio of -7.62 and a beta of 1.26. The firm’s fifty day moving average price is $28.02 and its two-hundred day moving average price is $31.07. Stoke Therapeutics has a fifty-two week low of $20.32 and a fifty-two week high of $40.22.

Insiders Place Their Bets

In related news, General Counsel Jonathan Allan sold 2,861 shares of Stoke Therapeutics stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $91,637.83. Following the completion of the transaction, the general counsel directly owned 21,225 shares of the company’s stock, valued at $679,836.75. The trade was a 11.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 7,176 shares of Stoke Therapeutics stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $29.04, for a total value of $208,391.04. Following the completion of the transaction, the insider directly owned 20,422 shares of the company’s stock, valued at $593,054.88. This represents a 26.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 34,594 shares of company stock valued at $1,069,305. 9.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on STOK shares. Guggenheim reiterated a “buy” rating and set a $60.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Chardan Capital reissued a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. JPMorgan Chase & Co. began coverage on shares of Stoke Therapeutics in a research report on Friday, August 21st. They issued an “overweight” rating and a $40.00 price target for the company. The Goldman Sachs Group restated a “buy” rating on shares of Stoke Therapeutics in a research note on Thursday, September 10th. Finally, Canaccord Genuity Group decreased their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.25.

About Stoke Therapeutics

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.